Abeona Therapeutics Reports $91.6 Million Net Income and Significant Asset Growth in Latest 10-Q

Abeona Therapeutics Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net income of $91.6 million for the nine months ended September 30, 2025, a substantial improvement compared to a net loss of $54.4 million for the same period in 2024. This turnaround was primarily driven by a $152.4 million gain from the sale of a Priority Review Voucher (PRV) following the FDA approval of its gene therapy product, ZEVASKYN®, in April 2025. The company also generated $400,000 in license and other revenues during the nine-month period, marking its first revenue from licensing activities.

In terms of operational expenses, Abeona's total costs and expenses for the nine months ended September 30, 2025, amounted to $66.9 million, up from $47.5 million in the previous year. The increase was largely attributed to a rise in selling, general, and administrative expenses, which surged to $46.2 million from $22.2 million, reflecting heightened commercialization efforts and legal costs associated with the launch of ZEVASKYN®. Research and development expenses decreased to $20.1 million from $25.4 million, as costs related to the product were capitalized into inventory following FDA approval.

Abeona's balance sheet showed a significant increase in total assets, rising to $231.1 million as of September 30, 2025, compared to $108.9 million at the end of 2024. This growth was fueled by a substantial increase in cash and cash equivalents, which reached $82.9 million, up from $23.4 million at the end of the previous fiscal year. The company also reported a total stockholders' equity of $171.2 million, a notable increase from $44.0 million at the end of 2024, reflecting the successful capital raises and the gain from the PRV sale.

Strategically, Abeona has made significant strides in expanding its product offerings and operational capabilities. The company activated a new Qualified Treatment Center for ZEVASKYN® at Children’s Hospital Colorado, enhancing patient access to its therapy. Additionally, the FDA selected Abeona's ABO-503 for X-linked retinoschisis for its Rare Disease Endpoint Advancement Pilot Program, which is expected to facilitate the development of the therapy. The company also appointed Dr. James A. Gow as Senior Vice President, Head of Clinical Development & Medical Affairs, to bolster its clinical expertise.

Looking ahead, Abeona anticipates continued investment in its research and development pipeline, particularly in advancing its AAV-based gene therapies for ophthalmic diseases. The company expects to maintain its current cash resources, which it believes are sufficient to fund operations for at least the next 12 months. However, it acknowledges the potential need for additional capital to support its ongoing commercialization and development efforts, particularly as it seeks to establish a market presence for ZEVASKYN® and other product candidates.